PressNovember 4, 2022 Beckley Psytech to Attend and Present at the Jefferies London Healthcare Conference – November 15-17, 2022
PressNovember 4, 2022 COMPASS Pathways Announces Third Quarter 2022 Financial Results and Business Highlights
PressNovember 3, 2022 Cybin to Participate in the Jefferies London Healthcare Conference and Upcoming Investor Events
PressNovember 3, 2022 MindMed to Host Earnings Call to Discuss Third Quarter 2022 Financial Results and Provide Business Update
PressNovember 3, 2022 First Patient Dosed in Clairvoyant’s Phase 2 Clinical Trial Exploring Psilocybin as a Treatment for Alcohol Use Disorder
PressNovember 3, 2022 COMPASS Pathways announces publication of phase 2b study of COMP360 psilocybin therapy for treatment-resistant depression in The New England Journal of Medicine
PressNovember 3, 2022 Silo Wellness Breaking News: Jackson County Oregon’s Proposed TPM Restrictions Put Rural Psilocybin Retreat Therapy Centers at Risk
PressNovember 2, 2022 Revitalist Releases Supplement Line to Enhance the Results of Psychedelic Medicines
PressNovember 2, 2022 Lusaris Therapeutics Launches with $60 Million Series A Financing to Redefine the Treatment of Severe Neuropsychiatric and Neurological Disorders
PressNovember 2, 2022 atai Life Sciences to Participate in November Investor Events & Healthcare Conferences
PressNovember 2, 2022 Braxia Scientific Announces Voting Results from the Annual General and Special Meeting of Shareholders
PressNovember 1, 2022 Revitalist Increases Patient Access Making Care More Affordable by Financing the Cost With M-Lend Financial
PressNovember 1, 2022 Cybin Announces Scientific Presentation at the 5th Annual Neuropsychiatric & Psychedelics Drug Development Summit
PressNovember 1, 2022 PharmaTher Enters into Exclusive Option Agreement with Case Western Reserve University to Develop and Commercialize Ketamine for Rett Syndrome
PressNovember 1, 2022 Irwin Naturals Looks to Add to Florida Foothold, Expanding Chain of Healthcare Clinics
PressNovember 1, 2022 Apex Labs Granted Approval for North America’s First Take Home Psilocybin Clinical Trial
PressNovember 1, 2022 Numinus Re-Launches “Psychedelic Therapy Frontiers” Podcast with additional hosts and topics
PressOctober 31, 2022 ENOSIS THERAPEUTICS AND OVID CLINICS ANNOUNCE PARTNERSHIP TO LAUNCH WORLD’S FIRST IN-CLINIC APPLICATION OF VIRTUAL REALITY MODULATED PSYCHEDELIC-AUGMENTED PSYCHOTHERAPY
PressOctober 31, 2022 Better U Expanding Psychedelic-Assisted Therapies to 9 States with Immersive Healing Centers
PressOctober 31, 2022 Small Pharma Receives Approval for First-In-Human Phase I Clinical Trial With SPL028
